SARS-CoV-2体液免疫应答机制及抗体检测技术研究进展

刘以诺; 史永林

doi:10.19837/j.cnki.ahyf.2024.06.012

PDF(821 KB)

安徽预防医学杂志 ›› 2024, Vol. 30 ›› Issue (6) : 484-489. DOI: 10.19837/j.cnki.ahyf.2024.06.012

综述

SARS-CoV-2体液免疫应答机制及抗体检测技术研究进展

刘以诺¹, 史永林^1,2

作者信息 +

Advances in SARS-CoV-2 humoral immune response mechanism and antibody detection techniques

LIU Yinuo¹, SHI Yonglin^1,2

Author information +

文章历史 +

摘要

近几年SARS-CoV-2以其极高的突变率和传染性在全球流行,COVID-19大流行成为引起国际关注的突发公共卫生事件。本文对SARS-CoV-2病原学特征、体液免疫应答特征、自然感染和疫苗接种后体液免疫应答和抗体检测技术的应用进行综述,为疫苗研发和公共卫生政策的制定提供科学依据。

Abstract

In recent years,SARS-CoV-2 has become a public health emergency of international concern due to its high mutation rate,and the COVID-19 pandemic has become a public health emergency of international concern.In this paper,we review the pathogenetic characteristics of SARS-CoV-2,the characteristics of humoral immune response to SARS-CoV-2,the humoral immune response to SARS-CoV-2 after natural infection and vaccination,and the application of SARS-CoV-2 antibody detection technology,in order to provide scientific basis for vaccine research and development,and the formulation of public health policies.

导出引用

刘以诺, 史永林. SARS-CoV-2体液免疫应答机制及抗体检测技术研究进展[J]. 安徽预防医学杂志. 2024, 30(6): 484-489 https://doi.org/10.19837/j.cnki.ahyf.2024.06.012

LIU Yinuo, SHI Yonglin. Advances in SARS-CoV-2 humoral immune response mechanism and antibody detection techniques[J]. Anhui Journal of Preventive Medicine. 2024, 30(6): 484-489 https://doi.org/10.19837/j.cnki.ahyf.2024.06.012

中图分类号： R373

参考文献

[1] Abbasian MH,Mahmanzar M,Rahimian K,et al.Global landscape of SARS-CoV-2 mutations and conserved regions[J].J Transl Med,2023,21(1):152.
[2] Geanes ES,McLennan R,LeMaster C,et al.Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity[J].Commun Med,2024,4(1):47.
[3] McCallum M,Walls AC,Bowen JE,et al.Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation[J].Nat Struct Mol Biol,2020,27(10):942-949.
[4] Mohamadian M,Chiti H,Shoghli A,et al.COVID-19:Virology,biology and novel laboratory diagnosis[J].J Gene Med,2021,23(2):e3303.
[5] V’Kovski P,Kratzel A,Steiner S,et al.Coronavirus biology and replication:implications for SARS-CoV-2[J].Nat Rev Microbiol,2021,19(3):155-170.
[6] Ju B,Zhang Q,Ge J,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection[J].Nature,2020,584(7819):115-119.
[7] Zhou P,Yang XL,Wang XG,et al.Addendum:a pneumonia outbreak associated with a new coronavirus of probable bat origin[J].Nature,2020,588(7836):E6.
[8] 徐宝丽,管甲亮,术超,等.新型冠状病毒COVID-19相关研究进展[J].中华医院感染学杂志,2020,30(6):839-844.
[9] Matinfar S,Mortezagholi S,Amiri D,et al.Investigating the seroconversion patterns of specific antibodies against various antigens of SARS-CoV-2 in hospitalized COVID-19 patients and vaccinated individuals[J].Arch Clin Infect Dis,2024,19(1):e140414.
[10] 吴雯,周贵香,施超,等.新型冠状病毒感染者特异性抗体变化特征分析[J].中国公共卫生,2022,38(6):804-807.
[11] 宋云,毋碧聪,卢世栋,等.新型冠状病毒肺炎患者血清IgM和IgG抗体动态变化分析[J].中华微生物学和免疫学杂志,2021,41(6):417-422.
[12] Zhao Z,Kumanovics A,Love T,et al.T cell responses correlate with self-reported disease severity and neutralizing antibody responses predict protection against SARS-CoV-2 breakthrough infection[J].Viruses,2023,15(3):709.
[13] Kumar A,Tripathi P,Kumar P,et al.From detection to protection:antibodies and their crucial role in diagnosing and combatting SARS-CoV-2[J].Vaccines,2024,12(5):459.
[14] 石慧春,焦凡珂,徐巍,等.靶向SARS-CoV-2受体结合结构域的嵌合抗体表达及功能研究[J].微生物与感染,2023,18(1):2-12.
[15] Xue JB,Tao SC.Epitope analysis of anti-SARS-CoV-2 neutralizing antibodies[J].Curr Med Sci,2021,41(6):1065-1074.
[16] 徐婧玥.新型冠状病毒抗体检测及应用[J].华北理工大学学报(医学版),2022,24(4):331-336.
[17] Chen X,Pan Z,Yue S,et al.Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19[J].Signal Transduct Target Ther,2020,5(1):180.
[18] Gaebler C,Wang Z,Lorenzi JCC,et al.Evolution of antibody immunity to SARS-CoV-2[J].Nature,2021,591(7851):639-644.
[19] Wajnberg A,Amanat F,Firpo A,et al.Robust neutralizing antibodies to SARS-CoV-2 infection persist for months[J].Science,2020,370(6521):1227-1230.
[20] 郭楠,姚雅萍,宋乐,等.新型冠状病毒感染后特异性抗体的动态变化[J].解放军医学院学报,2023,44(12):1344-1350.
[21] Feng C,Shi J,Fan Q,et al.Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery[J].Nat Commun,2021,12(1):4984.
[22] Li X,Yin Y,Pang L,et al.Colloidal gold immunochromatographic assay (GICA) is an effective screening method for identifying detectable anti-SARS-CoV-2 neutralizing antibodies[J].Int J Infect Dis,2021,108:483-486.
[23] 李幸乐,卢世栋,李金月,等.新型冠状病毒肺炎病例血清中和抗体动态变化及影响因素[J].中华实验和临床病毒学杂志,2021,35(3):341-344.
[24] Garcia-Beltran WF,Lam EC,St Denis K,et al.Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity[J].Cell,2021,184(9):2523.
[25] Luo WR,Wu XM,Wang W,et al.Novel coronavirus mutations:vaccine development and challenges[J].Microb Pathog,2022,173(Pt A):105828.
[26] 杨燕,王慧娟,黄保英,等.376例新冠肺炎恢复期与灭活疫苗接种后人群的血清抗体检测结果分析[J].国际病毒学杂志,2022,29(4):315-319.
[27] Szczepanek J,Skorupa M,Jarkiewicz-Tretyn J,et al.COVID-19 vaccination in healthcare workers:long-term benefits and protection[J].Cent Eur J Immunol,2023,48(4):311-321.
[28] Narowski TM,Raphel K,Adams LE,et al.SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people[J].Cell Rep,2022,38(5):110336.
[29] Schest S,Langer C,Stiegler Y,et al.Vaccine-induced SARS-CoV-2 antibody response:the comparability of S1-specific binding assays depends on epitope and isotype discrimination[J].Front Immunol,2023,14:1257265.
[30] Liu J,Yan W,Liu Z,et al.A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination[J].Med Nov Technol Devices,2021,11:100084.
[31] Díaz-Dinamarca DA,Díaz P,Barra G,et al.Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile[J].Front Public Health,2023,11:1229045.
[32] Anichini G,Terrosi C,Gori Savellini G,et al.Neutralizing antibody response of vaccinees to SARS-CoV-2 variants[J].Vaccines,2021,9(5):517.
[33] Karachaliou M,Moncunill G,Espinosa A,et al.SARS-CoV-2 infection,vaccination,and antibody response trajectories in adults:a cohort study in Catalonia[J].BMC Med,2022,20(1):347.
[34] 何军,罗婉蓉,夏艺丹,等.新型冠状病毒变异株的演化与研究进展[J].安徽预防医学杂志,2023,29(4):317-323+331.
[35] McDade TW,Sancilio A.Beyond serosurveys:human biology and the measurement of SARS-Cov-2 antibodies[J].Am J Hum Biol,2020,32(5):e23483.
[36] Zahirul Islam ZH.Comparison of rapid SARS- cov-2 antigen detection assay with real-time RT-PCR assay[J].Biomed J Sci Tech Res,2024,55(1):46549-46555.
[37] Muller DA,Depelsenaire AC,Young PR.Clinical and laboratory diagnosis of dengue virus infection[J].J Infect Dis,2017,215(suppl_2):S89-S95.
[38] Hosseini S,Vázquez-Villegas P,Rito-Palomares M,et al.Advantages,disadvantages and modifications of conventional ELISA[J].Enzyme-Linked Immunosorbent Assay (ELISA) from A to Z,2018:67-115.
[39] Hayrapetyan H,Tran T,Tellez-Corrales E,et al.Enzyme-linked immunosorbent assay:types and applications[J].Methods Mol Biol,2023,2612:1-17.
[40] Liu PP,Zong Y,Jiang SP,et al.Development of a nucleocapsid protein-based ELISA for detection of human IgM and IgG antibodies to SARS-CoV-2[J].ACS Omega,2021,6(14):9667-9671.
[41] Cinquanta L,Fontana DE,Bizzaro N.Chemiluminescent immunoassay technology:what does it change in autoantibody detection?[J].Auto Immun Highlights,2017,8(1):9.
[42] Wang C,Wu J,Zong C,et al.Chemiluminescent immunoassay and its applications[J].Chin J Anal Chem,2012,40(1):3-10.
[43] Ye L,Xu X,Song S,et al.Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination[J].J Mater Chem B,2022,10(11):1786-1794.
[44] Ye L,Lei X,Xu L,et al.Gold nanoparticle-based immunochromatographic assay for the rapid detection of the SARS-CoV-2 Omicron variant[J].Mater Chem Front,2023,7(18):4063-4072.
[45] Frische A,Brooks PT,Gybel-Brask M,et al.Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay[J].PLoS One,2022,17(7):e0272298.
[46] Liu KT,Han YJ,Wu GH,et al.Overview of neutralization assays and international standard for detecting SARS-CoV-2 neutralizing antibody[J].Viruses,2022,14(7):1560.
[47] Sun Y,Huang W,Xiang H,et al.SARS-CoV-2 neutralization assays used in clinical trials:a narrative review[J].Vaccines,2024,12(5):554.
[48] 胡燕,申鸽,李琼,等.2种SARS-CoV-2抗体检测方法在COVID-19诊断中的价值[J].检验医学,2020,35(12):1294-1297.
[49] 李芳彩,戴志辉,贺子翔,等.ELISA法与胶体金法在检测新型冠状病毒血清抗体中的应用探讨[J].实用预防医学,2020,27(7):780-783.
[50] Shen B,Zheng Y,Zhang X,et al.Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG[J].Am J Transl Res,2020,12(4):1348-1354.
[51] 陈维欣,陈萌,周珊珊,等.新型冠状病毒疫苗免疫后抗体水平检测的3种实验方法比较[J].中华微生物学和免疫学杂志,2021,41(6):423-426.
[52] Gilboa T,Cohen L,Cheng CA,et al.A SARS-CoV-2 neutralization assay using single molecule arrays[J].Angew Chem Int Ed,2021,60(49):25966-25972.
[53] Tan SS,Saw S,Chew KL,et al.Comparative clinical evaluation of the Roche elecsys and Abbott severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology assays for coronavirus disease 2019 (COVID-19)[J].Arch Pathol Lab Med,2021,145(1):32-38.